HC Wainwright Predicts Weaker Earnings for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD) – Investment analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Kodiak Sciences in a report issued on Monday, August 17th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($0.89) per share for the quarter, down from their prior forecast of ($0.80). HC Wainwright has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($3.27) EPS, FY2028 earnings at ($2.01) EPS, FY2029 earnings at $0.18 EPS and FY2030 earnings at $3.04 EPS.

Several other equities research analysts also recently weighed in on the company. Chardan Capital raised Kodiak Sciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $14.00 to $61.00 in a research report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Kodiak Sciences in a research note on Friday, July 10th. JPMorgan Chase & Co. raised their target price on Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Finally, Wall Street Zen cut Kodiak Sciences from a “hold” rating to a “sell” rating in a research report on Saturday. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $48.14.

Kodiak Sciences Price Performance

Shares of Kodiak Sciences stock opened at $40.65 on Wednesday. The stock has a market cap of $2.54 billion, a PE ratio of -9.70 and a beta of 2.21. The firm has a fifty day moving average price of $39.52 and a 200 day moving average price of $35.23. Kodiak Sciences has a 1 year low of $8.29 and a 1 year high of $47.84.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.09).

Hedge Funds Weigh In On Kodiak Sciences

A number of large investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company grew its position in shares of Kodiak Sciences by 31.8% in the first quarter. The Manufacturers Life Insurance Company now owns 120,629 shares of the company’s stock valued at $4,598,000 after purchasing an additional 29,121 shares during the period. California State Teachers Retirement System lifted its stake in Kodiak Sciences by 1,358.9% in the 1st quarter. California State Teachers Retirement System now owns 29,396 shares of the company’s stock valued at $1,121,000 after buying an additional 27,381 shares in the last quarter. Profund Advisors LLC purchased a new position in Kodiak Sciences in the 4th quarter valued at about $618,000. PSP Research LLC acquired a new stake in Kodiak Sciences in the 4th quarter worth about $543,000. Finally, Artia Global Partners LP acquired a new stake in Kodiak Sciences in the 4th quarter worth about $476,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical?stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.